Yuichi Ishikawa

Featured in: Favicon

nature.com Favicon

biomedcentral.com Favicon

jrheum.org Favicon

physiciansweekly.com Favicon

onlinelibrary.wiley.com Favicon

ard.bmj.com Favicon

arthritis-research.biomedcentral.com

Articles

Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database

Sep 19, 2023 | ard.bmj.com | Yuichi Ishikawa |Kei Tokutsu |Shingo Nakayamada |Aya Kuchiba

AbstractObjectives Life-threatening antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with rapidly progressive glomerulonephritis (RPGN) and/or alveolar haemorrhage (AH) has a poor prognosis. Rituximab (RTX) is as effective as cyclophosphamide (CY) in remission induction therapy; however, the effectiveness and safety of RTX have not been established in life-threatening AAV.
[Molecular targeted therapy for acute myeloid leukemia]

Jun 5, 2023 | pubmed.ncbi.nlm.nih.gov | Yuichi Ishikawa

Skip to main page content Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day?

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →